We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How TEM Is Capitalizing on AI-Driven Pathology Market Growth
Read MoreHide Full Article
Key Takeaways
Tempus AI acquired Paige, expanding its proprietary dataset and establishing a digital pathology presence.
Paige Predict analyzes H&E slides to predict 123 biomarkers and pathways across 16 cancer types for TEM.
TEM's Paige Predict integrates results into clinical reports for faster physician insights.
Investors are increasingly focused on the artificial intelligence (AI) in pathology market, which is expected to reach $1.15 billion by 2033, at a CAGR of 27.18% between 2025 and 2033 (per Grand View Research). This growth is being driven by the rising demand for precision medicine, the increasing prevalence of chronic diseases and rapid technological advancements in diagnostic tools.
Capitalizing on this momentum, Tempus AI (TEM - Free Report) acquired Paige, a leading AI-driven digital pathology company. Paige brings a deep foundation in pathology and AI, underpinned by its proprietary dataset of nearly 7 million clinically annotated, digitized pathology slides. The acquisition has significantly strengthened Tempus’ capabilities by expanding its proprietary dataset, enhancing its experienced technical workforce, and establishing a strong presence in digital pathology with an industry-leading technology portfolio.
Following the acquisition, Tempus launched Paige Predict, a suite of advanced digital pathology applications designed to analyze hematoxylin and eosin (H&E) whole-slide images to support informed testing decisions. Leveraging the combined intelligent digital pathology platform and proprietary AI technologies of Tempus and Paige, Paige Predict can extract critical biomarker insights from limited tissue samples and predict the likelihood of 123 biomarkers and oncogenic molecular pathways across 16 cancer types. These results are seamlessly integrated and automatically delivered to ordering physicians alongside clinical reports, enhancing diagnostic efficiency and precision.
Peer Update
In 2025, Labcorp (LH - Free Report) entered into a collaboration with Roche to implement its FDA-cleared VENTANA DP 600 and DP 200 slide scanners. Through this partnership, Labcorp will leverage Roche’s digital pathology technology to expand access, enhance efficiency, and support AI integration across its anatomic pathology services.
Labcorp’s Biopharma Laboratory Services business has also added digital pathology capabilities, including advanced image scanning and AI-powered solutions, to provide analysis on large data sets instantly. In May 2025, Labcorp entered into an agreement to acquire select technical assets of Incyte Diagnostics’ anatomic pathology (AP) business, including main AP laboratory in Spokane and its labs in Tukwila and Richland, WA, and Missoula, MT.
In 2025, Quest Diagnostics (DGX - Free Report) introduced a new AB 42/40 and p-tau-217 testing panel designed to support the identification of amyloid brain pathology in symptomatic patients. Earlier, in 2024, Quest Diagnostics acquired PathAI Diagnostics from PathAI, a strategic move aimed at accelerating the adoption of AI and digital pathology to enhance the diagnosis of cancer and other diseases. In conjunction with this acquisition, Quest Diagnostics also licensed PathAI’s AISight digital pathology image management platform to support its pathology laboratories and customer sites across the United States.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
How TEM Is Capitalizing on AI-Driven Pathology Market Growth
Key Takeaways
Investors are increasingly focused on the artificial intelligence (AI) in pathology market, which is expected to reach $1.15 billion by 2033, at a CAGR of 27.18% between 2025 and 2033 (per Grand View Research). This growth is being driven by the rising demand for precision medicine, the increasing prevalence of chronic diseases and rapid technological advancements in diagnostic tools.
Capitalizing on this momentum, Tempus AI (TEM - Free Report) acquired Paige, a leading AI-driven digital pathology company. Paige brings a deep foundation in pathology and AI, underpinned by its proprietary dataset of nearly 7 million clinically annotated, digitized pathology slides. The acquisition has significantly strengthened Tempus’ capabilities by expanding its proprietary dataset, enhancing its experienced technical workforce, and establishing a strong presence in digital pathology with an industry-leading technology portfolio.
Following the acquisition, Tempus launched Paige Predict, a suite of advanced digital pathology applications designed to analyze hematoxylin and eosin (H&E) whole-slide images to support informed testing decisions. Leveraging the combined intelligent digital pathology platform and proprietary AI technologies of Tempus and Paige, Paige Predict can extract critical biomarker insights from limited tissue samples and predict the likelihood of 123 biomarkers and oncogenic molecular pathways across 16 cancer types. These results are seamlessly integrated and automatically delivered to ordering physicians alongside clinical reports, enhancing diagnostic efficiency and precision.
Peer Update
In 2025, Labcorp (LH - Free Report) entered into a collaboration with Roche to implement its FDA-cleared VENTANA DP 600 and DP 200 slide scanners. Through this partnership, Labcorp will leverage Roche’s digital pathology technology to expand access, enhance efficiency, and support AI integration across its anatomic pathology services.
Labcorp’s Biopharma Laboratory Services business has also added digital pathology capabilities, including advanced image scanning and AI-powered solutions, to provide analysis on large data sets instantly. In May 2025, Labcorp entered into an agreement to acquire select technical assets of Incyte Diagnostics’ anatomic pathology (AP) business, including main AP laboratory in Spokane and its labs in Tukwila and Richland, WA, and Missoula, MT.
In 2025, Quest Diagnostics (DGX - Free Report) introduced a new AB 42/40 and p-tau-217 testing panel designed to support the identification of amyloid brain pathology in symptomatic patients. Earlier, in 2024, Quest Diagnostics acquired PathAI Diagnostics from PathAI, a strategic move aimed at accelerating the adoption of AI and digital pathology to enhance the diagnosis of cancer and other diseases. In conjunction with this acquisition, Quest Diagnostics also licensed PathAI’s AISight digital pathology image management platform to support its pathology laboratories and customer sites across the United States.